IBA (Ion Beam Applications S.A.), a global leader in particle accelerator and QA solutions, has introduced the QUASAR® GRID3D Advantage Image Distortion Analysis System during ESTRO 2025 in Vienna. The system is designed for healthcare providers needing high-precision MR distortion analysis in stereotactic planning and image-guided radiation therapy. It enables clinicians to evaluate and correct geometric distortion in MR images—critical for protecting healthy tissues during cancer treatment.

GRID3D Advantage offers automated analysis through user-friendly software and supports various MR setups, including frame adapters and frameless options. Its standout feature is compatibility with the Known Target Method in the Vantage Frame setup, which enhances the quality assurance process for Gamma Knife® radiosurgery and other stereotactic treatments. By providing accurate spatial validation, it ensures radiation beams are delivered with the highest precision.

With MR imaging becoming increasingly central to radiotherapy workflows, especially for small treatment fields, QA solutions like GRID3D Advantage are becoming indispensable. IBA Dosimetry President Jean-Marc Bothy emphasized that robust geometric fidelity is now essential, not optional. This product underscores IBA’s commitment to equipping clinicians with accurate, reliable tools to ensure optimal patient outcomes in advanced cancer care.

MedTech Spectrum's Summary

• Advanced QA for MR Distortion: GRID3D Advantage supports stereotactic planning by correcting MR image distortion using the Known Target Method.

• Streamlined & Flexible Use: Compatible with multiple MR setups, the system features automated software and versatile hardware adaptability.

• Critical for Precision Therapy: As MR gains prominence in radiation therapy, GRID3D helps safeguard treatment accuracy for small field cases and radiosurgery.